3 December 2021
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Group")
Director Dealings
Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that between 1 December 2021 and 3 December 2021 certain of the Company's Directors purchased shares as follow:
Name |
Date of Purchase |
No. of Shares Purchased |
Price per share |
Resultant holding post transaction (%) |
|
|
|
|
|
Jerry Randall, Chief Executive Officer |
3 December 2021 |
100,000 |
34.99p |
1,984,865 (1.5%) |
|
|
|
|
|
Sharon Collins, Chief Commercial Officer |
3 December 2021 |
100,000 |
34.99p |
1,109,977 (0.9%) |
|
|
|
|
|
Gianluca Braguti, Chief Manufacturing Officer |
3 December 2021 |
100,000 |
34.99p |
3,642,730 (2.9%) |
|
|
|
|
|
Carl Dempsey, Non-Executive Director |
1 December 2021 |
28,500 |
34.48 |
48,500 (0.04%) |
For further information, please contact:
Venture Life Group PLC |
+44 (0) 1344 578004 |
|
|
Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer |
|
|
|
Cenkos Securities plc (Nomad and Broker) |
+44 (0) 20 7397 8900 |
|
|
Stephen Keys / Camilla Hume |
|
|
|
Russell Kerr / Michael Johnson (Sales) |
|
|
|
|
|
|
|
N+1 Singer (Joint Broker) |
+44 (0) 20 7496 3000 |
|
|
Shaun Dobson / Alaina Wong (Corporate Finance) |
|
|
|
Jonathan Dighe (Sales) |
|
|
|
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|
a)
|
Name
|
Jerry Randall
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer |
b)
|
Initial notification /Amendment
|
Initial notification |
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Venture Life Group plc |
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
b)
|
Nature of the transaction
|
Purchase of ordinary shares |
c)
|
Price(s) and volume(s)
|
100,000 ordinary shares at 34.99 pence per share
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
See above
|
e)
|
Date of the transaction
|
3 December 2021 |
f)
|
Place of the transaction
|
London Stock Exchange
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|
a)
|
Name
|
Sharon Collins
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Commercial Officer |
b)
|
Initial notification /Amendment
|
Initial notification |
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Venture Life Group plc |
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
b)
|
Nature of the transaction
|
Purchase of ordinary shares |
c)
|
Price(s) and volume(s)
|
100,000 ordinary shares at 34.99 pence per share
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
See above
|
e)
|
Date of the transaction
|
3 December 2021 |
f)
|
Place of the transaction
|
London Stock Exchange
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
a)
|
Name
|
Gianluca Braguti
|
||||
2
|
Reason for the notification
|
|||||
a)
|
Position/status
|
Chief Manufacturing Officer |
||||
b)
|
Initial notification /Amendment
|
Initial notification |
||||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
a)
|
Name
|
Venture Life Group plc |
||||
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
||||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
||||
b)
|
Nature of the transaction
|
Purchase of ordinary shares |
||||
c)
|
Price(s) and volume(s)
|
|
||||
d)
|
Aggregated information
- Aggregated volume
- Price
|
See above
|
||||
e)
|
Date of the transaction
|
3 December 2021 |
||||
f)
|
Place of the transaction
|
London Stock Exchange
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
a)
|
Name
|
Carl Dempsey
|
||||
2
|
Reason for the notification
|
|||||
a)
|
Position/status
|
Non-Executive Director |
||||
b)
|
Initial notification /Amendment
|
Initial notification |
||||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
a)
|
Name
|
Venture Life Group plc |
||||
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
||||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
||||
b)
|
Nature of the transaction
|
Purchase of ordinary shares |
||||
c)
|
Price(s) and volume(s)
|
|
||||
d)
|
Aggregated information
- Aggregated volume
- Price
|
See above
|
||||
e)
|
Date of the transaction
|
1 December 2021 |
||||
f)
|
Place of the transaction
|
London Stock Exchange
|